IPSC
Century Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.80 / 10
Netural
Fund flow analysis scores 7.6/10, indicating robust liquidity with positive trends in block, medium, and large flows, despite minor negative signals in small and extra-large categories. Analyst consensus remains Buy across all coverage providers, but the most recent action—Clear Street lowering the price target to $6.60—adds a note of caution. Together, the strong fund inflows and bullish analyst stance partially offset the weak technicals.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-20
InstitutionPiper Sandler
Times predicted2
Historical Win Rate0.0%
What is the market sentiment for IPSC?
- IPSC holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 3.80/10 (Netural).
